NASDAQ:PULM - Pulmatrix Stock Price, Forecast & News

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

Pulmatrix's stock reverse split on Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

Pulmatrix Inc (NASDAQ:PULM) released its quarterly earnings data on Friday, November, 1st. The biotechnology company reported ($0.18) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.34) by $0.16. The biotechnology company had revenue of $1.41 million for the quarter. View Pulmatrix's Earnings History.

Pulmatrix is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Pulmatrix.

1 analysts have issued 12-month price targets for Pulmatrix's shares. Their forecasts range from $10.00 to $10.00. On average, they expect Pulmatrix's stock price to reach $10.00 in the next year. This suggests a possible upside of 584.9% from the stock's current price. View Analyst Price Targets for Pulmatrix.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pulmatrix.

News stories about PULM stock have been trending extremely negative recently, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pulmatrix earned a news impact score of -4.4 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Pulmatrix.

Pulmatrix saw a drop in short interest in February. As of February 14th, there was short interest totalling 857,900 shares, a drop of 7.3% from the January 30th total of 925,100 shares. Based on an average daily volume of 1,000,000 shares, the days-to-cover ratio is presently 0.9 days. Currently, 4.5% of the company's shares are sold short. View Pulmatrix's Current Options Chain.

Some companies that are related to Pulmatrix include Cassava Sciences (SAVA), Vaccinex (VCNX), TapImmune (MRKR), Corvus Pharmaceuticals (CRVS), Aldeyra Therapeutics (ALDX), AcelRx Pharmaceuticals (ACRX), IMMUTEP LTD/S (IMMP), Trevi Therapeutics (TRVI), Sunesis Pharmaceuticals (SNSS), Monopar Therapeutics (MNPR), Trillium Therapeutics (TRIL), Aquestive Therapeutics (AQST), Xeris Pharmaceuticals (XERS), Eton Pharmaceuticals (ETON) and Clearside Biomedical (CLSD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Verastem (VSTM), Cronos Group (CRON), Inovio Pharmaceuticals (INO), Neovasc (NVCN), Biopharmx (BPMX), Evoke Pharma (EVOK), TherapeuticsMD (TXMD), VBI Vaccines (VBIV) and Cara Therapeutics (CARA).

Pulmatrix's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.22%) and Acadian Asset Management LLC (0.48%). View Institutional Ownership Trends for Pulmatrix.

PULM stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Acadian Asset Management LLC. View Insider Buying and Selling for Pulmatrix.

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PULM stock can currently be purchased for approximately $1.46.

Pulmatrix has a market capitalization of $29.20 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-20,560,000.00 in net income (profit) each year or ($4.98) on an earnings per share basis. Pulmatrix employs 22 workers across the globe.View Additional Information About Pulmatrix.

The official website for Pulmatrix is http://www.pulmatrix.com/.

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]